Literature DB >> 21480376

The relationship between plasma amyloid-β peptides and the medial temporal lobe in the homebound elderly.

Xiaoyan Sun1, Rafeeque Bhadelia, Elizabeth Liebson, Peter Bergethon, Marshal Folstein, Jay-Jiguang Zhu, D Mkaya Mwamburi, Samuel Patz, Wei Qiao Qiu.   

Abstract

BACKGROUND: The ratio of high amyloid-β peptide40 (Aβ40) and low Aβ42 in plasma predicts the risk of Alzheimer's disease (AD) and is associated with episodic recall in depression. We thus examined the relationship between plasma Aβ levels and brain volumes.
METHODS: Homebound elders (N = 352) who had undergone brain MRI were used. Plasma Aβ1-40 and Aβ1-42 were measured by ELISA. Volumes of medial temporal regions, including the amygdala and hippocampus, were manually measured.
RESULTS: Amygdala volume was associated with log(10) of plasma Aβ1-42 (β = +0.19, SE = 0.07, p = 0.005) after adjusting for AD, infarcts, white matter hyperintensities and demographics. In the absence of dementia, decreasing quartiles of plasma Aβ1-42 (Mean + SD ml: Q4 = 4.1 ± 0.8; Q3 = 3.9 ± 0.7; Q2 = 3.6 ± 0.8 and Q1 = 3.7 ± 0.8, p = 0.01) and increasing quartiles of plasma Aβ1-40/1-42 ratio were associated with smaller amygdala volume. Those depressed subjects with a high plasma Aβ1-40/1-42 ratio had smaller amygdala (Mean + SD ml: 3.3 ± 0.8 vs. 3.6 ± 0.8, p = 0.04) and total brain volume (Mean + SD liter: 0.95 ± 0.07 vs. 1.04 ± 0.12, p = 0.005), and had a higher rate of MCI (67 vs. 36%, p = 0.02) than those with a low plasma Aβ1-40/1-42 ratio.
CONCLUSIONS: The combination of low plasma Aβ1-42 concentration and atrophy of the medial temporal lobe structures, which regulates mood and cognition, may represent a biomarker for a prodromal stage of AD.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21480376      PMCID: PMC5357567          DOI: 10.1002/gps.2568

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  47 in total

Review 1.  Biomarkers of Alzheimer disease in plasma.

Authors:  Michael C Irizarry
Journal:  NeuroRx       Date:  2004-04

2.  Different MRI findings for normal elderly and very mild Alzheimer's disease in a community: implications for clinical practice the Tajiri Project.

Authors:  Hiroshi Ishii; Kenichi Meguro; Satoshi Yamaguchi; Kazumi Hirayama; Michio Tabuchi; Etsuro Mori; Atsushi Yamadori
Journal:  Arch Gerontol Geriatr       Date:  2005-08-08       Impact factor: 3.250

3.  Medial temporal structures relate to memory impairment in Alzheimer's disease: an MRI volumetric study.

Authors:  E Mori; Y Yoneda; H Yamashita; N Hirono; M Ikeda; A Yamadori
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

4.  Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.

Authors:  M E Gurol; M C Irizarry; E E Smith; S Raju; R Diaz-Arrastia; T Bottiglieri; J Rosand; J H Growdon; S M Greenberg
Journal:  Neurology       Date:  2006-01-10       Impact factor: 9.910

5.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Authors:  T Kawarabayashi; L H Younkin; T C Saido; M Shoji; K H Ashe; S G Younkin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

6.  Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease.

Authors:  S Lehéricy; M Baulac; J Chiras; L Piérot; N Martin; B Pillon; B Deweer; B Dubois; C Marsault
Journal:  AJNR Am J Neuroradiol       Date:  1994-05       Impact factor: 3.825

7.  Performance characteristics of plasma amyloid-beta 40 and 42 assays.

Authors:  Olivia I Okereke; Weiming Xia; Michael C Irizarry; Xiaoyan Sun; Wei Q Qiu; Anne M Fagan; Pankaj D Mehta; Bradley T Hyman; Dennis J Selkoe; Francine Grodstein
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

8.  Volumetry of amygdala and hippocampus and memory performance in Alzheimer's disease.

Authors:  Michael Basso; John Yang; Lauren Warren; Martha G MacAvoy; Pradeep Varma; Richard A Bronen; Christopher H van Dyck
Journal:  Psychiatry Res       Date:  2006-03-09       Impact factor: 3.222

9.  Prodromal Alzheimer's disease: successive emergence of the clinical symptoms.

Authors:  Hélène Amieva; Mélanie Le Goff; Xavier Millet; Jean Marc Orgogozo; Karine Pérès; Pascale Barberger-Gateau; Hélène Jacqmin-Gadda; Jean François Dartigues
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422

Review 10.  Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature.

Authors:  Liana G Apostolova; Jeffrey L Cummings
Journal:  Dement Geriatr Cogn Disord       Date:  2007-12-14       Impact factor: 2.959

View more
  6 in total

1.  Soluble amyloid-β levels and late-life depression.

Authors:  Ricardo S Osorio; Tyler Gumb; Nunzio Pomara
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

2.  Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimer's disease and vascular dementia.

Authors:  Sema Uslu; Zubeyde Eken Akarkarasu; Demet Ozbabalik; Serhat Ozkan; Omer Colak; Emine Sutken Demirkan; Ayşe Ozkiris; Canan Demirustu; Ozkan Alatas
Journal:  Neurochem Res       Date:  2012-03-22       Impact factor: 3.996

3.  Clinical prediction of fall risk and white matter abnormalities: a diffusion tensor imaging study.

Authors:  Bang-Bon Koo; Peter Bergethon; Wei Qiao Qiu; Tammy Scott; Mohammed Hussain; Irwin Rosenberg; Louis R Caplan; Rafeeque A Bhadelia
Journal:  Arch Neurol       Date:  2012-06

4.  Plasma beta amyloid level and depression in older adults.

Authors:  Andrea L Metti; Jane A Cauley; Anne B Newman; Hilsa N Ayonayon; Lisa C Barry; Lewis M Kuller; Suzanne Satterfield; Eleanor M Simonsick; Kristine Yaffe
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-04-12       Impact factor: 6.053

5.  Age and its association with low insulin and high amyloid-β peptides in blood.

Authors:  Huajie Li; Haihao Zhu; Max Wallack; Mkaya Mwamburi; Samer O Abdul-Hay; Malcolm A Leissring; Wei Qiao Qiu
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

6.  Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease.

Authors:  H Zhu; X Wang; M Wallack; H Li; I Carreras; A Dedeoglu; J-Y Hur; H Zheng; H Li; R Fine; M Mwamburi; X Sun; N Kowall; R A Stern; W Q Qiu
Journal:  Mol Psychiatry       Date:  2014-03-11       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.